Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D, Tejpar S, Vergote I, Coosemans A, Garg AD.
Sprooten J, et al. Among authors: garg ad.
J Immunother Cancer. 2021 Nov;9(11):e003609. doi: 10.1136/jitc-2021-003609.
J Immunother Cancer. 2021.
PMID: 34795003
Free PMC article.